Primary objective | To assess the treatment effect of L-BLP25 plus BSC, as compared to BSC alone, on overall survival time |
Secondary objectives | Time to symptom progression (based on LCSS questionnaire) |
 | Time to progression |
 | Progression-free survival time |
 | Time to treatment failure |
 | Safety |
Other objectives | Quality-of-life (EQ-5D/LCSS) |
 | Healthcare resource utilization and work status |
 | Biomarkers/pharmacogenetics |